Title A Phase II Study of the Efficacy, Safety and Determinants of Response to 5-Azacitidine (Vidaza®) in Patients with Chronic Myelomonocytic Leukemia (CMML)
Principal Investigator Meir Wetzler, MD
Study Number 206011
Summary The specific purpose of the study is to: Find out what effects the study drug has on your cancer, CMML. The study drug is FDA-approved for the treatment of CMML and has been used to treat CMML. This is because very few of the subjects in the clinical trials had this specific type of cancer. A cycle is 28 days. You will be given the study drug, 5-azacitidine (Vidaza), on days 1 through 7 of each cycle. You will need to come to the infusion clinic to receive your study drug. This drug is given by injection under the skin (subcutaneously) or into a vein (intravenously). If intravenous administration of study drug is not feasible then you may receive your study drug as a subcutaneous injection throughout the duration of the study. You will repeat this treatment every 28 days for at least 8 cycles and up to a maximum of 24 cycles, as long as you tolerate it and your disease responds.
Eligibility Please see ClinicalTrials.gov link above.